paclitaxel + S-1 + oxaliplatin

This is a combination chemotherapy regimen consisting of paclitaxel (a microtubule-stabilizing agent), S-1 (an oral fluoropyrimidine derivative combining tegafur, gimeracil, and oteracil), and oxaliplatin (a platinum-based DNA crosslinker). The regimen is primarily investigated for advanced gastric cancer with peritoneal metastasis. Paclitaxel is often administered intraperitoneally to maximize local drug exposure in the peritoneum, while S-1 and oxaliplatin are given systemically. This combination leverages the synergistic cytotoxic effects of these agents to improve tumor response rates in patients with advanced or metastatic disease[1][2]. The mechanism involves inhibition of cell division via microtubule stabilization (paclitaxel), DNA crosslinking leading to apoptosis (oxaliplatin), and inhibition of thymidylate synthase/DNA synthesis (S-1)[1][2]. Clinical studies have shown promising efficacy as induction chemotherapy for patients with peritoneal metastases from gastric cancer[2].

Other names

paclitaxel plus S-1 plus oxaliplatinIP-PTX + SOXSOX + IP-PTX